Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MET overexpression
i
Other names:
DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4233
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
(32)
News
Trials
Search handles
@HHorinouchi
@StephenVLiu
@tpjmd
Search handles
@HHorinouchi
@StephenVLiu
@tpjmd
Filter by
Latest
12ms
MET-specialist ADC in MET amplification: Preliminary Efficacy of Telisotuzumab Vedotin Treatment in the 2L/3L Setting in MET Gene Amplified, c-Met Protein Overexpressing, Non-squamous, NSCLC: Retrospective Analysis of LUMINOSITY by Dr. Ross Camidge. #AACR23 #LCSM (@HHorinouchi)
12 months ago
Retrospective data
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET overexpression
|
telisotuzumab vedotin (ABBV-399)
1year
Dr. Paul Paik explains how to navigate #MET in managing NSCLC. We have capmatinib and tepotinib approved for METex14 mutations - effective (but watch for toxicity). In the future - MET amplification and MET overexpression (IHC) likely to be relevant! #TexasLung23 (@StephenVLiu)
1 year ago
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET overexpression • MET amplification + MET overexpression
|
Tepmetko (tepotinib) • Tabrecta (capmatinib)
1year
Telisotuzumab vedotin (Teliso-V, an ADC targeting Met) monotherapy @JSMO_official. An ORR of 52.2% was demonstrated in patients with high c-Met–overexpression (≥50% tumor cells at 3+ staining intensity) non-sq NSCLC without EGFR mutation. #JSMO2023 #LCSM (@HHorinouchi)
1 year ago
Clinical • Tumor cell
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET overexpression
|
telisotuzumab vedotin (ABBV-399)
1year
Telisotuzumab vedotin (Teliso-V, an ADC targeting Met) plus osimertinib @JSMO_official. An ORR of 50% was demonstrated in patients with EGFR-mutated, c-Met–overexpressing (≥25% tumor cells at 3+ staining intensity) NSCLC after progression on prior Osimertinib. #JSMO2023 #LCSM (@HHorinouchi)
1 year ago
Clinical • Tumor cell
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • MET overexpression • MET mutation
|
Tagrisso (osimertinib) • telisotuzumab vedotin (ABBV-399)
over1year
Very helpful narrative review of #MET and its role in NSCLC @JTOonline. Covers approved and emerging agents. With MET, need to distinguish #METex14 mutations, MET amplification, and MET overexpression - as implications of each are quite different. #LCSM https://t.co/i6BZG8L7vT (@StephenVLiu)
over 1 year ago
Review
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET overexpression • MET mutation
almost2years
Hypothesis-generating: Addition of afatanib to patients c/ EGFR over-expressing met gastric cancer should be explored. Addition of IO to chemo (or in place of chemo) for periop Rx of resectable gastric cancer should be explored, esp among pts c/ MSI-H/dMMR/hPDL1CPS tumors. (@tpjmd)
almost 2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability)
|
MSI-H/dMMR • EGFR expression • EGFR overexpression • MET overexpression • MET expression
over2years
#ESMO21 #MET can be dysregulated in many different ways. Dr. Pascale Tomasini highlights the difference between MET overexpression, amplification, mutation, fusion. MET also mediates resistance to other targets like #KRAS but with clonal heterogeneity, these can co-exist. #LCSM (@StephenVLiu)
over 2 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • MET overexpression • MET mutation
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login